News & Updates
Filter by Specialty:
Ribociclib–binimetinib combo safe, effective in NRAS-mutant melanoma
Treatment with the combination of ribociclib plus binimetinib appears to be well tolerated and delivers modest clinical activity in patients with locally advanced or metastatic melanoma harbouring NRAS mutation, according to the results of a phase Ib/II study.
Ribociclib–binimetinib combo safe, effective in NRAS-mutant melanoma
22 Jul 2022
Investigational nitric oxide gel for water warts scores high in phase III trial
A novel nitric oxide-releasing gel, berdazimer 10.3%, proves effective in the treatment of patients with water warts or molluscum contagiosum skin infection, facilitating clearance of lesions with low adverse event rates, as shown in the phase III B-SIMPLE4 trial.
Investigational nitric oxide gel for water warts scores high in phase III trial
21 Jul 2022
Isotretinoin does not hurt patients’ mental health, study says
While treatment with isotretinoin for acne is said to have a negative impact on mental health, its use appears to instead mitigate the excess psychiatric risk associated with treatment-resistant moderate-to-severe acne, as reported in a large study.
Isotretinoin does not hurt patients’ mental health, study says
11 Jul 2022
TNFi use carries only modest increase in psoriasis risk
The use of tumour necrosis factor-α inhibitor (TNFi) for inflammatory bowel disease (IBD) or rheumatoid arthritis (RA) raises the risk of developing psoriasis by twofold as compared with conventional therapy, although the absolute risk remains modest, as reported in a study.